This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Nov 15;33(14):2263-2264.

doi: 10.1097/QAD.0000000000002330.

Response to letter to the editor: switch to dolutegravir and unboosted atazanavir

Antonio Di Biagio¹, Laura Magnasco, Giovanni Cenderello, Giuliano Rizzardini

Affiliations

Affiliation

¹ aInfectious Diseases Unit, San Martino Policlinic Hospital bInfectious Diseases Unit, Department of Health's Sciences, University of Genoa cInfectious Diseases Unit, Galliera Hospital, Genoa dDepartment of Infectious Diseases, Sacco Hospital, Milan, Italy.

PMID: 31688044
DOI: 10.1097/QAD.0000000000002330

Comment

Response to letter to the editor: switch to dolutegravir and unboosted atazanavir

Antonio Di Biagio et al. AIDS. 2019.

. 2019 Nov 15;33(14):2263-2264.

doi: 10.1097/QAD.0000000000002330.

Authors

Antonio Di Biagio¹, Laura Magnasco, Giovanni Cenderello, Giuliano Rizzardini

Affiliation

¹ aInfectious Diseases Unit, San Martino Policlinic Hospital bInfectious Diseases Unit, Department of Health's Sciences, University of Genoa cInfectious Diseases Unit, Galliera Hospital, Genoa dDepartment of Infectious Diseases, Sacco Hospital, Milan, Italy.

PMID: 31688044
DOI: 10.1097/QAD.0000000000002330

No abstract available

PubMed Disclaimer

Comment in

Two-drug regimens with dolutegravir for maintaining viral suppression: looking at the right companion.
Castagna A; DAU Study Group. Castagna A, et al. AIDS. 2019 Nov 15;33(14):2264-2266. doi: 10.1097/QAD.0000000000002329. AIDS. 2019. PMID: 31688045 No abstract available.

Comment on

Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy.
Castagna A, Rusconi S, Gulminetti R, Bonora S, Mazzola G, Quiros-Roldan ME, De Socio GV, Ladisa N, Carosella S, Cattelan A, Di Giambenedetto S, Mena M, Poli A, Galli L, Riva A; DAU Study Group. Castagna A, et al. AIDS. 2019 Jun 1;33(7):1256-1260. doi: 10.1097/QAD.0000000000002188. AIDS. 2019. PMID: 30870194

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.